Abstract: Objective  To investigate the clinical efficacy of atorvastatin in early intervention of postmenopausal breast cancer patients.
Methods  A total of 200 cases of postmenopausal breast cancer were selected and divided into control group (100 cases) and research group (100 cases) according to random number table method. In control group, patients were given letrozole, while in study group, patients were given atorvastatin calcium on this basis. Both groups were treated for 2 years. The blood lipid levels, cardiovascular events, recurrence and metastasis of breast cancer before treatment, 12 months after treatment and 24 months after treatment were compared between two groups.
Results  The levels of blood lipid in two groups were higher after the treatment than before the treatment(P＜0.01), but the level of blood lipid in the study group was significantly lower than that in the control group after 12 and 24 months of treatment(P＜0.01). However, the blood lipid level of the study group was significantly lower than that of the control group after 12 months of treatment(P＜0.05). The incidence of cardiovascular events(MACE) in the study group was significantly lower than that in control group(P＜0.05). The recurrence and metastasis rate of breast cancer in the study group was significantly lower than that in the control group(P＜0.05).
Conclusion  Atorvastatin can not only effectively regulate the dyslipidemia caused by letrozole in postmenopausal breast cancer patients, but also help to reduce the incidence of cardiovascular events and do not affect the treatment of breast cancer.

Key words: breast cancer, postmenopause, Atorvastatin calcium